Marker Therapeutics, Inc (MRKR)

Etorro trading 970x250
Marker Therapeutics, Inc (MRKR) Logo

About Marker Therapeutics, Inc

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas. Address: Phoenix Tower, Houston, TX, United States, 77027

Marker Therapeutics, Inc News and around…

Latest news about Marker Therapeutics, Inc (MRKR) common stock and company :

Marker Therapeutics Reports Q1 2022 Operating and Financial Results
13 May, 2022 Yahoo! Finance

Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinical trials to be initiated in 2023 HOUSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a

12 Health Care Stocks Moving In Thursday's After-Market Session
05 May, 2022 FinancialContent

Gainers iRhythm Technologies (NASDAQ:IRTC) stock increased by 30.2% to $153.75 during Thursday's after-market session. Trading volume ...

Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting
04 May, 2022 Yahoo! Finance

HOUSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company will present four posters on its Multi-Tumor-Associated Antigen (MultiTAA)-specific T cell therapies at the 2022 International Society for Cell & Gene Therapy (ISCT) Annual Meeting, bei

The Daily Biotech Pulse - Tuesday, April,26
26 Apr, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours.

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag
26 Apr, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Protagonist's Ulcerative ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
26 Apr, 2022 FinancialContent

Gainers Agile Therapeutics (NASDAQ:AGRX) shares increased by 45.7% to $0.2 during Tuesday's pre-market session. The ...

Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf
26 Apr, 2022 Yahoo! Finance

HOUSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced it has entered into a services agreement with Wilson Wolf Manufacturing Corporation. The agreement includes an $8.0 million upfront cash payment by Wilson Wolf to Marker in exchange for services relat

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
25 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Another day of investing awaits for traders as we start it off with a breakdown of the biggest pre-market stock movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
20 Apr, 2022 FinancialContent

Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 40.0% to $1.4 during Wednesday's pre-market session. The ...

66 Biggest Movers From Yesterday
23 Mar, 2022 FinancialContent

Gainers JX Luxventure Limited (NASDAQ: LLL) shares jumped 119.5% to settle at $4.39 on Tuesday after the company announced it ...

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results
17 Mar, 2022 Yahoo! Finance

Enrollment of first 20 patients of the Company’s Phase 2 acute myeloid leukemia (AML) trial completed in Q4 2021 Topline readout of Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinical trials to be initiated in 2023 HOUSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapi

Marker Therapeutics to Present at Two Upcoming March Investor Conferences
07 Mar, 2022 Yahoo! Finance

HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Anthony H. Kim, Chief Financial Officer of Marker Therapeutics, will present at two upcoming investor conferences in March. Conference Details ROTH Annual ConferenceFireside ChatDate: Monday, Marc

80 Biggest Movers From Yesterday
02 Mar, 2022 FinancialContent

Gainers Avenue Therapeutics, Inc.(NASDAQ: ATXI) jumped 78.5% to close at $0.6066 on Tuesday after jumping 36% on ...

12 Health Care Stocks Moving In Monday's After-Market Session
28 Feb, 2022 FinancialContent

Gainers GBS (NASDAQ:GBS) stock rose 10.9% to $0.51 during Monday's after-market session. The market value of their outstanding shares ...

Stocks That Hit 52-Week Lows On Friday
18 Feb, 2022 FinancialContent

On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
18 Feb, 2022 FinancialContent

Gainers Biofrontera (NASDAQ:BFRA) stock moved upwards by 11.8% to $3.49 during Friday's pre-market session. The ...

60 Biggest Movers From Yesterday
18 Feb, 2022 FinancialContent

Gainers Inspirato Incorporated (NASDAQ: ISPO) shares climbed 618.2% to close at $92.65 on Thursday, just a few days after the ...

Why Are Marker Therapeutics Shares Trading Lower On Thursday?
17 Feb, 2022 FinancialContent

Marker Therapeutics Inc(NASDAQ: MRKR) shares are trading lower after Roth Capital downgrades the company fromBuy to Neutral ...

12 Health Care Stocks Moving In Thursday's Intraday Session
17 Feb, 2022 FinancialContent

Gainers Rhythm Pharmaceuticals (NASDAQ:RYTM) stock increased by 16.4% to $7.72 during Thursday's regular session. ...

Stocks That Hit 52-Week Lows On Thursday
17 Feb, 2022 FinancialContent

On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week ...

Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2022
17 Feb, 2022 FinancialContent

Upgrades HSBC upgraded the previous rating for Equinor ASA (NYSE:EQNR) from Hold to Buy. For the fourth quarter, Equinor had an EPS of ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
17 Feb, 2022 FinancialContent

Gainers NeuroOne Medical Tech (NASDAQ:NMTC) shares moved upwards by 12.3% to $3.0 during Thursday's pre-market ...

Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion
16 Feb, 2022 Yahoo! Finance

Results from safety lead-in stage of Marker’s Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading New T cell manufacturing process for MT-401 and other product candidates designed to improve potency, increase antigen specificity and diversity and significantly reduce manufacturing time Company announces clinical updates, including plans to file additional INDs by year end, with clinical trial

Earnings Scheduled For February 16, 2022
16 Feb, 2022 FinancialContent

Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on ...

Earnings Preview: Marker Therapeutics
15 Feb, 2022 FinancialContent

Marker Therapeutics (NASDAQ:MRKR) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors ...

Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022
08 Feb, 2022 Yahoo! Finance

HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, February 16, 2022 at 5:00 p.m. EST to provide an update on the Company’s clinical programs, manufacturing processes and pipeline. The webcas

53 Biggest Movers From Friday
24 Jan, 2022 FinancialContent

Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on ...

12 Health Care Stocks Moving In Friday's Intraday Session
21 Jan, 2022 FinancialContent

Gainers Biophytis (NASDAQ:BPTS) shares rose 12.3% to $5.28 during Friday's regular session. The market value of ...

34 Stocks Moving In Friday's Mid-Day Session
21 Jan, 2022 FinancialContent

Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares jumped 180% to $5.32 after gaining around 9% on Thursday. Bon Natural Life ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
21 Jan, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! Let's close out the week right with a breakdown of the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Marker Therapeutics, Inc (MRKR) is a NASDAQ Common Stock listed in , ,

970x250